Regulation of Mcl-1 Expression in Context to Bone Marrow Stromal Microenvironment in Chronic Lymphocytic Leukemia

Neoplasia (United States)

Volumn 16, Issue 12, 2014, Pages 1036-1046

  Balakrishnan, Kumudha ^a   Burger, Jan A ^a   Fu, Min ^a   Doifode, Tejaswini ^a   Wierda, William G ^a   Gandhi, Varsha ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN KINASE B; PROTEIN MCL 1; MCL1 PROTEIN, HUMAN; MESSENGER RNA;

APOPTOSIS; ARTICLE; B LYMPHOCYTE; BONE MARROW STROMA CELL; CANCER PROGNOSIS; CELL PROLIFERATION; CELL PROTECTION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; GENE AMPLIFICATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RNA SYNTHESIS; SUSPENSION CELL CULTURE; TUMOR MICROENVIRONMENT; ADULT; AGED; BLOOD; BONE MARROW CELL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; REAL TIME POLYMERASE CHAIN REACTION; STROMA CELL; TUMOR CELL CULTURE;

ADULT; AGED; BONE MARROW CELLS; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; PROTO-ONCOGENE PROTEINS C-BCL-2; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; STROMAL CELLS; TUMOR CELLS, CULTURED;

EID: 85003294616     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1016/j.neo.2014.10.002     Document Type: Article

References (51)

1. Pepper, C., Lin, T.T., Pratt, G., Hewamana, S., Brennan, P., Hiller, L., Hills, R., Ward, R., Starczynski, J., Austen, B., et al. Mcl‐1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 112 (2008), 3807–3817.
2. Balakrishnan, K., Wierda, W.G., Keating, M.J., Gandhi, V., Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 112 (2008), 1971–1980.
3. Ghiotto, F., Fais, F., Tenca, C., Tomati, V., Morabito, F., Casciaro, S., Mumot, A., Zoppoli, G., Ciccone, E., Parodi, S., et al. Apoptosis of B‐cell chronic lymphocytic leukemia cells induced by a novel BH3 peptidomimetic. Cancer Biol Ther 8 (2009), 263–271.
4. Chen, R., Keating, M.J., Gandhi, V., Plunkett, W., Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood 106 (2005), 2513–2519.
5. Burger, M., Hartmann, T., Krome, M., Rawluk, J., Tamamura, H., Fujii, N., Kipps, T.J., Burger, J.A., Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood 106 (2005), 1824–1830.
6. Longo, P.G., Laurenti, L., Gobessi, S., Sica, S., Leone, G., Efremov, D.G., The Akt/Mcl‐1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B‐cell receptor in chronic lymphocytic leukemia B cells. Blood 111 (2008), 846–855.
7. Petlickovski, A., Laurenti, L., Li, X., Marietti, S., Chiusolo, P., Sica, S., Leone, G., Efremov, D.G., Sustained signaling through the B‐cell receptor induces Mcl‐1 and promotes survival of chronic lymphocytic leukemia B cells. Blood 105 (2005), 4820–4827.
8. Balakrishnan, K., Burger, J.A., Quiroga, M.P., Henneberg, M., Ayres, M.L., Wierda, W.G., Gandhi, V., Influence of bone marrow stromal microenvironment on forodesine‐induced responses in CLL primary cells. Blood 116 (2010), 1083–1091.
9. Balakrishnan, K., Burger, J.A., Wierda, W.G., Gandhi, V., AT‐101 induces apoptosis in CLL B cells and overcomes stromal cell‐mediated Mcl‐1 induction and drug resistance. Blood 113 (2009), 149–153.
10. Kurtova, A.V., Balakrishnan, K., Chen, R., Ding, W., Schnabl, S., Quiroga, M.P., Sivina, M., Wierda, W.G., Estrov, Z., Keating, M.J., et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug‐induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion‐mediated drug resistance. Blood 114 (2009), 4441–4450.
11. Burger, J.A., Tsukada, N., Burger, M., Zvaifler, N.J., Dell'Aquila, M., Kipps, T.J., Blood‐derived nurselike cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell‐derived factor‐1. Blood 96 (2000), 2655–2663.
12. Pedersen, I.M., Kitada, S., Leoni, L.M., Zapata, J.M., Karras, J.G., Tsukada, N., Kipps, T.J., Choi, Y.S., Bennett, F., Reed, J.C., Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl‐1. Blood 100 (2002), 1795–1801.
13. Vogler, M., Butterworth, M., Majid, A., Walewska, R.J., Sun, X.M., Dyer, M.J., Cohen, G.M., Concurrent up‐regulation of BCL‐XL and BCL2A1 induces approximately 1000‐fold resistance to ABT‐737 in chronic lymphocytic leukemia. Blood 113 (2009), 4403–4413.
14. Baudot, A.D., Jeandel, P.Y., Mouska, X., Maurer, U., Tartare‐Deckert, S., Raynaud, S.D., Cassuto, J.P., Ticchioni, M., Deckert, M., The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome‐dependent regulation of Mcl‐1 expression. Oncogene 28 (2009), 3261–3273.
15. Paterson, A., Mockridge, C.I., Adams, J.E., Krysov, S., Potter, K.N., Duncombe, A.S., Cook, S.J., Stevenson, F.K., Packham, G., Mechanisms and clinical significance of BIM phosphorylation in chronic lymphocytic leukemia. Blood 119 (2012), 1726–1736.
16. Epling‐Burnette, P.K., Liu, J.H., Catlett‐Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J.M., Yang‐Yen, H.F., Karras, J., et al. Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl‐1 expression. J Clin Invest 107 (2001), 351–362.
17. Karin, M., Lin, A., NF‐kappaB at the crossroads of life and death. Nat Immunol 3 (2002), 221–227.
18. Ricci, M.S., Kim, S.H., Ogi, K., Plastaras, J.P., Ling, J., Wang, W., Jin, Z., Liu, Y.Y., Dicker, D.T., Chiao, P.J., et al. Reduction of TRAIL‐induced Mcl‐1 and cIAP2 by c‐Myc or sorafenib sensitizes resistant human cancer cells to TRAIL‐induced death. Cancer Cell 12 (2007), 66–80.
19. Wang, J.M., Chao, J.R., Chen, W., Kuo, M.L., Yen, J.J., Yang‐Yen, H.F., The antiapoptotic gene mcl‐1 is up‐regulated by the phosphatidylinositol 3‐kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19 (1999), 6195–6206.
20. Malin, S., McManus, S., Busslinger, M., STAT5 in B cell development and leukemia. Curr Opin Immunol 22 (2010), 168–176.
21. Chauhan, D., Uchiyama, H., Akbarali, Y., Urashima, M., Yamamoto, K., Libermann, T.A., Anderson, K.C., Multiple myeloma cell adhesion‐induced interleukin‐6 expression in bone marrow stromal cells involves activation of NF‐kappa B. Blood 87 (1996), 1104–1112.
22. Ghosh, A.K., Secreto, C.R., Knox, T.R., Ding, W., Mukhopadhyay, D., Kay, N.E., Circulating microvesicles in B‐cell chronic lymphocytic leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 115 (2010), 1755–1764.
23. Ricciardi, M.R., Petrucci, M.T., Gregorj, C., Ariola, C., Lemoli, R.M., Fogli, M., Mauro, F.R., Cerretti, R., Foa, R., Mandelli, F., et al. Reduced susceptibility to apoptosis correlates with kinetic quiescence in disease progression of chronic lymphocytic leukaemia. Br J Haematol 113 (2001), 391–399.
24. Patel, V., Chen, L.S., Wierda, W.G., Balakrishnan, K., Gandhi, V., Impact of bone marrow stromal cells on Bcl‐2 family members in chronic lymphocytic leukemia. Leuk Lymphoma 55 (2014), 899–910.
25. Chen, L.S., Balakrishnan, K., Gandhi, V., Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol 80 (2010), 1936–1945.
26. Gandhi, V., Balakrishnan, K., Chen, L.S., Mcl‐1: the 1 in CLL. Blood 112 (2008), 3538–3540.
27. Balakrishnan, K., Stellrecht, C.M., Genini, D., Ayres, M., Wierda, W.G., Keating, M.J., Leoni, L.M., Gandhi, V., Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP. Blood 105 (2005), 4455–4462.
28. Huang, P., Sandoval, A., Van Den Neste, E., Keating, M.J., Plunkett, W., Inhibition of RNA transcription: a biochemical mechanism of action against chronic lymphocytic leukemia cells by fludarabine. Leukemia 14 (2000), 1405–1413.
29. Kitada, S., Zapata, J.M., Andreeff, M., Reed, J.C., Protein kinase inhibitors flavopiridol and 7‐hydroxy‐staurosporine down‐regulate antiapoptosis proteins in B‐cell chronic lymphocytic leukemia. Blood 96 (2000), 393–397.
30. Chen, R., Wierda, W.G., Chubb, S., Hawtin, R.E., Fox, J.A., Keating, M.J., Gandhi, V., Plunkett, W., Mechanism of action of SNS‐032, a novel cyclin‐dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 113 (2009), 4637–4645.
31. Tong, W.G., Chen, R., Plunkett, W., Siegel, D., Sinha, R., Harvey, R.D., Badros, A.Z., Popplewell, L., Coutre, S., Fox, J.A., et al. Phase I and pharmacologic study of SNS‐032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 28 (2010), 3015–3022.
32. Lin, T.S., Ruppert, A.S., Johnson, A.J., Fischer, B., Heerema, N.A., Andritsos, L.A., Blum, K.A., Flynn, J.M., Jones, J.A., Hu, W., et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high‐risk disease. J Clin Oncol 27 (2009), 6012–6018.
33. Yang, T., Buchan, H.L., Townsend, K.J., Craig, R.W., MCL‐1, a member of the BLC‐2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 166 (1996), 523–536.
34. Domina, A.M., Vrana, J.A., Gregory, M.A., Hann, S.R., Craig, R.W., MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene 23 (2004), 5301–5315.
35. Messmer, D., Fecteau, J.F., O'Hayre, M., Bharati, I.S., Handel, T.M., Kipps, T.J., Chronic lymphocytic leukemia cells receive RAF‐dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib. Blood 117 (2011), 882–889.
36. Inoshita, S., Takeda, K., Hatai, T., Terada, Y., Sano, M., Hata, J., Umezawa, A., Ichijo, H., Phosphorylation and inactivation of myeloid cell leukemia 1 by JNK in response to oxidative stress. J Biol Chem 277 (2002), 43730–43734.
37. Kobayashi, S., Lee, S.H., Meng, X.W., Mott, J.L., Bronk, S.F., Werneburg, N.W., Craig, R.W., Kaufmann, S.H., Gores, G.J., Serine 64 phosphorylation enhances the antiapoptotic function of Mcl‐1. J Biol Chem 282 (2007), 18407–18417.
38. Zhong, Q., Gao, W., Du, F., Wang, X., Mule/ARF‐BP1, a BH3‐only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl‐1 and regulates apoptosis. Cell 121 (2005), 1085–1095.
39. Inuzuka, H., Shaik, S., Onoyama, I., Gao, D., Tseng, A., Maser, R.S., Zhai, B., Wan, L., Gutierrez, A., Lau, A.W., et al. SCF(FBW7) regulates cellular apoptosis by targeting MCL1 for ubiquitylation and destruction. Nature 471 (2011), 104–109.
40. Schwickart, M., Huang, X., Lill, J.R., Liu, J., Ferrando, R., French, D.M., Maecker, H., O'Rourke, K., Bazan, F., Eastham‐Anderson, J., et al. Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature 463 (2010), 103–107.
41. Maurer, U., Charvet, C., Wagman, A.S., Dejardin, E., Green, D.R., Glycogen synthase kinase‐3 regulates mitochondrial outer membrane permeabilization and apoptosis by destabilization of MCL‐1. Mol Cell 21 (2006), 749–760.
42. Doble, B.W., Woodgett, J.R., GSK‐3: tricks of the trade for a multi‐tasking kinase. J Cell Sci 116 (2003), 1175–1186.
43. Grimes, C.A., Jope, R.S., The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65 (2001), 391–426.
44. Ding, Q., He, X., Xia, W., Hsu, J.M., Chen, C.T., Li, L.Y., Lee, D.F., Yang, J.Y., Xie, X., Liu, J.C., et al. Myeloid cell leukemia‐1 inversely correlates with glycogen synthase kinase‐3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 67 (2007), 4564–4571.
45. Ding, Q., He, X., Hsu, J.M., Xia, W., Chen, C.T., Li, L.Y., Lee, D.F., Liu, J.C., Zhong, Q., Wang, X., et al. Degradation of Mcl‐1 by beta‐TrCP mediates glycogen synthase kinase 3‐induced tumor suppression and chemosensitization. Mol Cell Biol 27 (2007), 4006–4017.
46. Herman, S.E., Gordon, A.L., Wagner, A.J., Heerema, N.A., Zhao, W., Flynn, J.M., Jones, J., Andritsos, L., Puri, K.D., Lannutti, B.J., et al. Phosphatidylinositol 3‐kinase‐delta inhibitor CAL‐101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 116 (2010), 2078–2088.
47. Collins, R.J., Harmon, B.V., Souvlis, T., Pope, J.H., Kerr, J.F., Effects of cycloheximide on B‐chronic lymphocytic leukaemic and normal lymphocytes in vitro: induction of apoptosis. Br J Cancer 64 (1991), 518–522.
48. Chen, R., Guo, L., Chen, Y., Jiang, Y., Wierda, W.G., Plunkett, W., Homoharringtonine reduced Mcl‐1 expression and induced apoptosis in chronic lymphocytic leukemia. Blood 117 (2011), 156–164.
49. Brown, J.R., Byrd, J.C., Coutre, S.E., Benson, D.M., Flinn, I.W., Wagner‐Johnston, N.D., Spurgeon, S.E., Kahl, B.S., Bello, C., Webb, H.K., et al. Idelalisib, an inhibitor of phosphatidylinositol 3‐kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 123 (2014), 3390–3397.
50. Rahmani, M., Davis, E.M., Bauer, C., Dent, P., Grant, S., Apoptosis induced by the kinase inhibitor BAY 43–9006 in human leukemia cells involves down‐regulation of Mcl‐1 through inhibition of translation. J Biol Chem 280 (2005), 35217–35227.
51. Kozopas, K.M., Yang, T., Buchan, H.L., Zhou, P., Craig, R.W., MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. Proc Natl Acad Sci U S A 90 (1993), 3516–3520.